Solid Bio gets a new CEO, $75M cash and drops lead drug as big investors jury-rig a merger deal

John Carroll

Editor & Founder

Three months after Endpoints News broke the story that gene therapy outfit AavantiBio had gutted its CMC group in a reorganization, the biotech’s CEO …

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.

BECOME A PREMIUM SUBSCRIBER

Solid Bio gets a new CEO, $75M cash and drops lead drug as big investors jury-rig a merger deal

John Carroll

Editor & Founder

Sign up to read this article for free.

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy

Sol­id Bio gets a new CEO, $75M cash and drops lead drug as big in­vestors ju­ry-rig a merg­er deal

John Carroll

Editor & Founder

Sign up to read this article for free.

more like this

No­var­tis to cut 139 jobs in NJ as part of com­mer­cial re­fo­cus

Ap­plied Ther­a­peu­tic­s' rare dis­ease drug gets a CRL

Idor­sia eyes lay­offs, tees up Tryvio li­cens­ing deal to ex­tend cash run­way

Ad­vanz Phar­ma faces re­vo­ca­tion of Eu­ro­pean au­tho­riza­tion for liv­er dis­ease drug Ocali­va

PTC re­ports Phase 2 ALS fail, sells pri­or­i­ty re­view vouch­er for $150M

FDA is look­ing in­to hema­tol­ogy risks af­ter pa­tients take Blue­bird's Skysona gene ther­a­py

Solid Bio gets a new CEO, $75M cash and drops lead drug as big investors jury-rig a merger deal

Novartis to cut 139 jobs in NJ as part of commercial refocus

Applied Therapeutics' rare disease drug gets a CRL

Idorsia eyes layoffs, tees up Tryvio licensing deal to extend cash runway

Advanz Pharma faces revocation of European authorization for liver disease drug Ocaliva

PTC reports Phase 2 ALS fail, sells priority review voucher for $150M

FDA is looking into hematology risks after patients take Bluebird's Skysona gene therapy